200 related articles for article (PubMed ID: 31183579)
21. Graft-vs.-lymphoma effect in various histologies of non-Hodgkin's lymphoma.
Maloney DG
Leuk Lymphoma; 2003; 44 Suppl 3():S99-105. PubMed ID: 15202532
[TBL] [Abstract][Full Text] [Related]
22. Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and High-Dose Rituximab for Allogeneic Hematopoietic Cell Transplantation for Follicular Lymphoma: A Phase Two Multicenter Trial from the Blood and Marrow Transplant Clinical Trials Network.
Laport GG; Wu J; Logan B; Bachanova V; Hosing C; Fenske T; Longo W; Devine SM; Nademanee A; Gersten I; Horowitz M; Lazarus HM; Riches ML;
Biol Blood Marrow Transplant; 2016 Aug; 22(8):1440-1448. PubMed ID: 27118571
[TBL] [Abstract][Full Text] [Related]
23. Reduced intensity conditioning for allogeneic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: where do we stand?
Anderlini P; Champlin RE
Biol Blood Marrow Transplant; 2006 Jun; 12(6):599-602. PubMed ID: 16737932
[TBL] [Abstract][Full Text] [Related]
24. Clinical outcome following autologous and allogeneic blood and marrow transplantation for relapsed diffuse large-cell non-Hodgkin's lymphoma.
Aksentijevich I; Jones RJ; Ambinder RF; Garrett-Mayer E; Flinn IW
Biol Blood Marrow Transplant; 2006 Sep; 12(9):965-72. PubMed ID: 16920563
[TBL] [Abstract][Full Text] [Related]
25. Allogeneic transplantation in lymphoma: current status.
Schmitz N; Dreger P; Glass B; Sureda A
Haematologica; 2007 Nov; 92(11):1533-48. PubMed ID: 18024402
[TBL] [Abstract][Full Text] [Related]
26. Long-term results of blood and marrow transplantation for Hodgkin's lymphoma.
Akpek G; Ambinder RF; Piantadosi S; Abrams RA; Brodsky RA; Vogelsang GB; Zahurak ML; Fuller D; Miller CB; Noga SJ; Fuchs E; Flinn IW; O'Donnell P; Seifter EJ; Mann RB; Jones RJ
J Clin Oncol; 2001 Dec; 19(23):4314-21. PubMed ID: 11731514
[TBL] [Abstract][Full Text] [Related]
27. Fluctuating lymphocyte chimerism, tolerance and anti-tumor response in a patient with refractory lymphoma receiving nonmyeloablative conditioning and a haploidentical related allogeneic bone marrow transplant.
Toh HC; Spitzer TR; Preffer F; Alexander SI; McAfee S; Dombkowski D; Clark JS; Colby C; Saidman S; Sackstein R; Sykes M
Cytokines Cell Mol Ther; 2002 Dec; 7(2):43-7. PubMed ID: 12607794
[TBL] [Abstract][Full Text] [Related]
28. Establishment of early donor engraftment after reduced-intensity allogeneic hematopoietic stem cell transplantation to potentiate the graft-versus-lymphoma effect against refractory lymphomas.
Bishop MR; Hou JW; Wilson WH; Steinberg SM; Odom J; Castro K; Kasten-Sportes C; Gea-Banacloche J; Marchigiani D; Gress R; Fowler DH
Biol Blood Marrow Transplant; 2003 Mar; 9(3):162-9. PubMed ID: 12652466
[TBL] [Abstract][Full Text] [Related]
29. Donor T-lymphocyte infusion for unrelated allogeneic bone marrow transplantation with CD3+ T-cell-depleted graft.
Lee CK; deMagalhaes-Silverman M; Hohl RJ; Hayashi M; Buatti J; Wen BC; Schlueter A; Strauss RG; Gingrich RD
Bone Marrow Transplant; 2003 Jan; 31(2):121-8. PubMed ID: 12621494
[TBL] [Abstract][Full Text] [Related]
30. [Study on nonmyeloablative allogeneic bone marrow transplantation in the treatment of L615 leukemia mice].
Xu KL; Ju JP; Pan XY; Du B; Li ZY; Lu QX
Zhonghua Xue Ye Xue Za Zhi; 2003 Jul; 24(7):372-5. PubMed ID: 12941194
[TBL] [Abstract][Full Text] [Related]
31. Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.
Gürman G; Arat M; Ilhan O; Konuk N; Beksaç M; Celebi H; Ozcan M; Arslan O; Ustün C; Akan H; Uysal A; Koç H
Cytotherapy; 2001; 3(4):253-60. PubMed ID: 12171713
[TBL] [Abstract][Full Text] [Related]
32. [Effects of immature dendritic cells genetically modified to express sTNFR I on graft-versus-host disease (GVHD) and graft-versus-leukemia (GVL) in allogeneic bone marrow transplantation mice].
Wang SH; Li DP; Zhang YJ; Zhang P; Zeng LY; Pan XY; Xu KL; Huang YH
Zhonghua Xue Ye Xue Za Zhi; 2012 Feb; 33(2):88-93. PubMed ID: 22730654
[TBL] [Abstract][Full Text] [Related]
33. High-dose therapy and blood or marrow transplantation for non-Hodgkin lymphoma with central nervous system involvement.
Kasamon YL; Jones RJ; Piantadosi S; Ambinder RF; Abrams RA; Borowitz MJ; Morrison C; Smith BD; Flinn IW
Biol Blood Marrow Transplant; 2005 Feb; 11(2):93-100. PubMed ID: 15682069
[TBL] [Abstract][Full Text] [Related]
34. Allogeneic haematopoietic stem-cell transplantation for relapsed and refractory aggressive histology non-Hodgkin lymphoma.
Doocey RT; Toze CL; Connors JM; Nevill TJ; Gascoyne RD; Barnett MJ; Forrest DL; Hogge DE; Lavoie JC; Nantel SH; Shepherd JD; Sutherland HJ; Voss NJ; Smith CA; Song KW
Br J Haematol; 2005 Oct; 131(2):223-30. PubMed ID: 16197454
[TBL] [Abstract][Full Text] [Related]
35. Allogeneic bone marrow transplantation in patients with follicular lymphoma: a single center study.
Yakoub-Agha I; Fawaz A; Folliot O; Guillerm G; Quesnel B; Fenaux P; Bauters F; Jouet JP; Morschhauser F
Bone Marrow Transplant; 2002 Aug; 30(4):229-34. PubMed ID: 12203139
[TBL] [Abstract][Full Text] [Related]
36. Transplantation for non-Hodgkin lymphoma.
Nademanee A
Expert Rev Hematol; 2009 Aug; 2(4):425-42. PubMed ID: 21082947
[TBL] [Abstract][Full Text] [Related]
37. Controversies in autologous and allogeneic hematopoietic cell transplantation in peripheral T/NK-cell lymphomas.
Shustov A
Best Pract Res Clin Haematol; 2013 Mar; 26(1):89-99. PubMed ID: 23768643
[TBL] [Abstract][Full Text] [Related]
38. Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide.
McCurdy SR; Kasamon YL; Kanakry CG; Bolaños-Meade J; Tsai HL; Showel MM; Kanakry JA; Symons HJ; Gojo I; Smith BD; Bettinotti MP; Matsui WH; Dezern AE; Huff CA; Borrello I; Pratz KW; Gladstone DE; Swinnen LJ; Brodsky RA; Levis MJ; Ambinder RF; Fuchs EJ; Rosner GL; Jones RJ; Luznik L
Haematologica; 2017 Feb; 102(2):391-400. PubMed ID: 27846611
[TBL] [Abstract][Full Text] [Related]
39. Rituximab-containing reduced-intensity conditioning improves progression-free survival following allogeneic transplantation in B cell non-Hodgkin lymphoma.
Epperla N; Ahn KW; Ahmed S; Jagasia M; DiGilio A; Devine SM; Jaglowski S; Kennedy V; Rezvani AR; Smith SM; Sureda A; Fenske TS; Kharfan-Dabaja MA; Armand P; Hamadani M
J Hematol Oncol; 2017 Jun; 10(1):117. PubMed ID: 28606176
[TBL] [Abstract][Full Text] [Related]
40. Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin's lymphoma.
Thomson KJ; Morris EC; Bloor A; Cook G; Milligan D; Parker A; Clark F; Yung L; Linch DC; Chakraverty R; Peggs KS; Mackinnon S
J Clin Oncol; 2009 Jan; 27(3):426-32. PubMed ID: 19064981
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
